365 related articles for article (PubMed ID: 24307201)
1. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice.
Zheng T; Zhang T; Zhang R; Wang ZL; Han ZL; Li N; Li XH; Zhang MN; Xu B; Yang XL; Fang Q; Wang R
Neuropeptides; 2017 Jun; 63():83-90. PubMed ID: 28010996
[TBL] [Abstract][Full Text] [Related]
3. CB
Zheng T; Zhang R; Zhang T; Zhang MN; Xu B; Song JJ; Li N; Tang HH; Wang P; Wang R; Fang Q
Brain Res; 2018 Feb; 1680():155-164. PubMed ID: 29274880
[TBL] [Abstract][Full Text] [Related]
4. The hypotensive effect of intrathecally injected (m)VD-hemopressin(α) in urethane-anesthetized rats.
Li XH; Li N; Wang ZL; Pan JX; Han ZL; Chang XM; Tang HH; Wang P; Wang R; Fang Q
Peptides; 2014 Jun; 56():45-51. PubMed ID: 24681436
[TBL] [Abstract][Full Text] [Related]
5. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
Zhang RS; He Z; Jin WD; Wang R
Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221
[TBL] [Abstract][Full Text] [Related]
6. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Wang P; Zheng T; Zhang M; Xu B; Zhang R; Zhang T; Zhao W; Shi X; Zhang Q; Fang Q
Brain Res Bull; 2018 May; 139():48-55. PubMed ID: 29425797
[TBL] [Abstract][Full Text] [Related]
8. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice.
Pan JX; Wang ZL; Li N; Zhang N; Wang P; Tang HH; Zhang T; Yu HP; Zhang R; Zheng T; Fang Q; Wang R
Eur J Pharmacol; 2015 Nov; 767():119-25. PubMed ID: 26472125
[TBL] [Abstract][Full Text] [Related]
9. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects.
Xu B; Xiao J; Xu K; Zhang Q; Chen D; Zhang R; Zhang M; Zhu H; Niu J; Zheng T; Li N; Zhang X; Fang Q
Neuropharmacology; 2020 Sep; 175():108178. PubMed ID: 32544481
[TBL] [Abstract][Full Text] [Related]
10. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
11. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice.
Pan JX; Wang ZL; Li N; Han ZL; Li XH; Tang HH; Wang P; Zheng T; Fang Q; Wang R
Neurosci Lett; 2014 Aug; 578():187-91. PubMed ID: 25010019
[TBL] [Abstract][Full Text] [Related]
12. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
13. An α-hemoglobin-derived peptide (m)VD-hemopressin (α) promotes NREM sleep via the CB
Xie JF; Wang LX; Ren WT; Wang C; Gao JX; Chen HL; Zhao XQ; Ren YL; Xie YP; Shao YF; Hou YP
Front Pharmacol; 2023; 14():1213215. PubMed ID: 37456761
[TBL] [Abstract][Full Text] [Related]
14. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
[TBL] [Abstract][Full Text] [Related]
15. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice.
Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA
J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060
[TBL] [Abstract][Full Text] [Related]
16. Central functional response to the novel peptide cannabinoid, hemopressin.
Dodd GT; Worth AA; Hodkinson DJ; Srivastava RK; Lutz B; Williams SR; Luckman SM
Neuropharmacology; 2013 Aug; 71():27-36. PubMed ID: 23542442
[TBL] [Abstract][Full Text] [Related]
17. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
da Fonseca Pacheco D; Klein A; de Castro Perez A; da Fonseca Pacheco CM; de Francischi JN; Duarte ID
Br J Pharmacol; 2008 Jul; 154(5):1143-9. PubMed ID: 18469844
[TBL] [Abstract][Full Text] [Related]
18. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.
Curto-Reyes V; Boto T; Hidalgo A; Menéndez L; Baamonde A
Eur J Pharmacol; 2011 Oct; 668(1-2):184-9. PubMed ID: 21771590
[TBL] [Abstract][Full Text] [Related]
20. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
